Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial.

@article{Casper2008ValganciclovirFS,
  title={Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial.},
  author={Corey Casper and Elizabeth M. Krantz and Lawrence Corey and Steven R Kuntz and Jie Wang and Stacy S Selke and Shannon Hamilton and Meei-li Huang and Anna Wald},
  journal={The Journal of infectious diseases},
  year={2008},
  volume={198 1},
  pages={
          23-30
        }
}
BACKGROUND Human herpesvirus-8 (HHV-8) replication is critical in the induction and maintenance of Kaposi sarcoma, primary effusion lymphoma, and some cases of Castleman disease. In vitro and observational studies suggest that ganciclovir inhibits HHV-8 replication, but no randomized clinical trials have been conducted. METHODS A total of 26 men infected with HHV-8 were randomized to receive 8 weeks of valganciclovir administered orally (900 mg once per day) or 8 weeks of placebo administered… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 59 CITATIONS

FILTER CITATIONS BY YEAR

2008
2017

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES

Kaposi's sarcoma.

  • The New England journal of medicine
  • 2000
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients.

  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2005
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…